A recent study published in The Lancet has raised alarms about the increasing resistance to antibiotics in treating bloodstream infections.
This significant rise in resistance from January 2017 to December 2022 is particularly concerning for public health officials worldwide.
Study Findings and Antibiotic Resistance
The study, titled “Emerging trends in antimicrobial resistance in bloodstream infections: a multicentric longitudinal study in India,” reveals that common bloodstream infections (BSIs) caused by bacteria such as Klebsiella, E. coli, and Acinetobacter have shown a marked resistance to critical antibiotics like Imipenem and Meropenem.
These infections, if not effectively treated, can be fatal.
Data Collection and Analysis
Researchers from the Center of Excellence in Healthcare at Indraprastha Institute of Information Technology, Delhi, Department of Computational Biology, Division of Biomedical Informatics, and Indian Council of Medical Research (ICMR) conducted the study.
They retrospectively analyzed data collected over six years from 21 tertiary care centers part of the Indian Council of Medical Research’s AMR Surveillance Network (IAMRSN).
The data aimed to estimate trends in antimicrobial resistance.
Global and Indian Context
The study highlighted that in 2017, approximately 49 million sepsis cases were recorded globally, leading to around 11 million deaths.
Alarmingly, 41 percent of these affected individuals were children. In India alone, about 11 million people were affected by sepsis in 2017, resulting in 3 million deaths.
This high percentage underscores the critical impact of antimicrobial resistance (AMR) in low and middle-income countries.
Rising Resistance Trends
“Our findings indicate significant monthly increases in Imipenem and Meropenem resistance for Klebsiella, E. coli, and Acinetobacter BSIs,” the study stated.
This resistance trend poses a serious threat, as the shrinking pipeline of new drugs could lead to a global health crisis reminiscent of a pandemic.
Broader Implications of AMR
The study underscores that AMR has become a global crisis. In 2019 alone, approximately 4.5 million deaths were attributed to AMR.
Projections suggest that this number could escalate to 10 million deaths annually by 2050 if the trend continues unabated.
The situation is exacerbated in countries with lower per capita income due to higher rates of infectious diseases, increased antibiotic use, and the impact of the COVID-19 pandemic.
Hospitalization and Mortality Data
Between 2017 and 2022, around 511,000 people, including both children and adults, were hospitalized due to infections caused by drug-resistant pathogens.
These pathogens are part of the World Health Organization’s list of global priority pathogens.
The study noted a significant rise in infection-related deaths due to multidrug-resistant pathogens, increasing from 7,879 cases in 2017 to 21,092 cases in 2022.
Call for Immediate Action
The study’s authors emphasized the urgent need for targeted interventions to combat the escalating AMR crisis.
“Our findings underscore the urgency of the escalating AMR crisis and its implications for broader development goals.
This necessitates immediate and targeted interventions, including further research, increased funding, and the formulation of effective local policies for AMR containment,” the research added.
The rise in antibiotic resistance among common bloodstream infections poses a severe threat to global health.
Immediate actions, such as increased funding for research, the development of new antibiotics, and the implementation of effective local and global policies, are essential to combating this crisis.
The findings of this study serve as a stark reminder of the critical need to address antimicrobial resistance before it leads to even more devastating consequences for public health.
The information is taken from various journals and recent research.
